Anticholinergic burden and cognitive performance: cross-sectional results from the ELSA-Brasil study

Imagem de Miniatura
Arquivos
art_SANTOS_Anticholinergic_burden_and_cognitive_performance_crosssectional_results_from_2022.PDF (694.25 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER HEIDELBERG
Autores
VIANA, Maria Carmen
Citação
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, v.78, n.9, p.1527-1534, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives Using multiple drugs with anticholinergic properties is common and might lead to cumulative anticholinergic toxicity and increased risk of cognitive impairment. Therefore, we sought to investigate the association between the Anticholinergic Cognitive Burden (ACB) Scale and cognitive performance among middle-aged and older adults. Methods In this cross-sectional study with 13,065 participants from the baseline visit of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), mean age was 51.7 +/- 9.0 years old, 55% women, and 53% white. The ACB was calculated based on the medications in use. We investigated the association of ACB with global cognition and memory, verbal fluency (VF), and trail-making test version B (TMT-B) z-scores, using multiple linear regression models adjusted for sociodemographic and clinical variables. Results Overall, 16% of participants had an ACB score greater than 0. ACB was associated with poor cognitive performance in all tests in crude analysis. After adjustment for sociodemographic characteristics, the association remained significant for the global cognitive score, as well as the memory and the TMT-B z-scores. However, after further adjustments for clinical variables, only trend associations of ACB with poor memory (beta = - 0.02, 95% Cl = - 0.05, 0.00, p = 0.056) and the TMT-B z-scores (beta = - 0.02, 95% Cl = - 0.04, 0.00, p = 0.054) were found. In stratified analyses by age groups, ACB was associated with poor cognitive performance on the TMT-B (beta = - 0.03, 95% Cl = - 0.05, - 0.01, p = 0.005) in individuals aged less than 65 years old. Conclusion Although the ACB was associated with poor executive function only among middle-aged adults in adjusted analysis, residual confounding may partly explain our results.
Palavras-chave
Anticholinergic burden, Cognition, Dementia, Drug utilization
URI
https://observatorio.fm.usp.br/handle/OPI/49104
Referências
  1. Aiolfi Claucia Raquel, 2015, Rev. bras. geriatr. gerontol., V18, P397, DOI 10.1590/1809-9823.2015.14035
  2. Akiyama Haruhiko, 2011, Nihon Rinsho, V69 Suppl 10 Pt 2, P264
  3. Albuquerque EX, 2009, PHYSIOL REV, V89, P73, DOI 10.1152/physrev.00015.2008
  4. Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
  5. Bertolucci PHF, 2001, ARQ NEURO-PSIQUIAT, V59, P532, DOI 10.1590/S0004-282X2001000400009
  6. Block CK, 2015, ARCH CLIN NEUROPSYCH, V30, P105, DOI 10.1093/arclin/acu073
  7. Borja-Oliveira, 2017, EFEITOS CARGA ANTICO, V22
  8. Boustani M., 2008, AGING HLTH, V4, P311, DOI [DOI 10.2217/1745509X.4.3.311, 10.2217/1745509X.4.3.311, 10.2217/1745509XA3.311]
  9. Brombo G, 2018, DRUG AGING, V35, P917, DOI 10.1007/s40266-018-0584-9
  10. Chor D, 2013, REV SAUDE PUBL, V47, P27, DOI 10.1590/S0034-8910.2013047003835
  11. Chuang Yi-Fang, 2017, Alzheimers Dement (N Y), V3, P471, DOI 10.1016/j.trci.2017.06.004
  12. Passos VMD, 2014, SAO PAULO MED J, V132, P170, DOI 10.1590/1516-3180.2014.1323646
  13. Ellett LMK, 2014, J AM GERIATR SOC, V62, P1916, DOI 10.1111/jgs.13054
  14. Farrell B, 2014, CAN FAM PHYSICIAN, V60, P345
  15. Pitanga FJG, 2018, ARQ BRAS CARDIOL, V110, P36, DOI 10.5935/abc.20170178
  16. Gray Shelly L, 2016, Ther Adv Drug Saf, V7, P217
  17. Hafdi M, 2020, J AM MED DIR ASSOC, V21, P188, DOI 10.1016/j.jamda.2019.05.010
  18. Iyer S, 2020, INT UROGYNECOL J, V31, P2653, DOI 10.1007/s00192-019-04140-3
  19. Koyama A, 2014, J GERONTOL A-BIOL, V69, P423, DOI 10.1093/gerona/glt192
  20. Landi F, 2014, J AM MED DIR ASSOC, V15, P825, DOI 10.1016/j.jamda.2014.08.002
  21. Moriarty F, 2021, BRIT J CLIN PHARMACO, V87, P2818, DOI 10.1111/bcp.14687
  22. Nunes MA, 2011, REV HCPA, V31, P487
  23. Pasina L, 2013, DRUG AGING, V30, P103, DOI 10.1007/s40266-012-0044-x
  24. Passos Valéria Maria de Azeredo, 2018, Braz. J. Nephrol., V40, P18, DOI [10.1590/1678-4685-JBN-3889, 10.1590/1678-4685-jbn-3889]
  25. Pierce H, 2019, EUR UROL, V76, P7, DOI 10.1016/j.eururo.2019.03.021
  26. Richardson K, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1315
  27. Schmidt MI, 2015, INT J EPIDEMIOL, V44, P68, DOI 10.1093/ije/dyu027
  28. Secoli SR, 2010, REV BRAS ENFERM, V63, P136, DOI 10.1590/S0034-71672010000100023
  29. Shah RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064111
  30. Taylor-Rowan M, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013540.pub2
  31. Tune LE, 2001, J CLIN PSYCHIAT, V62, P11
  32. Ventura ALM, 2010, REV PSIQ CLIN-BRAZIL, V37, P66

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - LIM/22
Artigos e Materiais de Revistas Científicas - LIM/27
Artigos e Materiais de Revistas Científicas - LIM/51
Carregar mais